DESCRIPTIONPERSONNELRIGORSERVICESPUBLICATIONS

HIV/STD Laboratory CORE DESCRIPTION

The HIV/STD Laboratory Core of the UNC CFAR offers services and collaborations to HIV researchers for their basic and clinical research projects. The Core provides a CAP/CLIA accredited environment for testing, although we currently have few assays on the CAP menu. However, we can offer testing for the diagnosis of HIV, Neisseria gonorrheae, Chlamydia tractomatis, Trichomonas vaginalis, and Mycoplasma genitalium. In addition, the Core provides specimen processing for clinical trials taking place at UNC.

The HIV/STD Laboratory Core consults and collaborates with researchers at UNC-CH, RTI International, and FHI 360 (as well as outside researchers). Our contributions to recent research projects include:

  • developing flow cytometry assays and cytokine ELISA and multiplex bead array panels
  • providing instrumentation, e.g. ELISPOT reader
  • sequencing of HIV from patients
  • testing new microbiologic diagnostic assays on a variety of specimen types
  • testing compounds for anti-HIV activity
  • measuring prostate specific antigen (PSA) as a marker of sexual activity
  • training of personnel in virus work and various assays

The Core serves as a repository for long- and short-term storage of biological specimens from HIV+ patients in the UNC Clinical Cohort and maintains a current CDC-USPHS permit for importing HIV+ specimens from foreign countries.

Researchers and clinicians can request services using the button at the top of the page and you can contact us by our email address.

Microscopic images of HIV particles, CD4+ cell, and cell infected with N. gonorrhoeae

 

HIV/STD Laboratory CORE NEWS

The CAP/CLIA part of the HIV/STD Laboratory Core is currently located on the 2nd floor of the Genome Sciences Building (behind the hospital) near the Bell Tower parking deck, and this part fo the Core will be moving to the 5th floor of Taylor Hall in November. The Basic Science part of the Core lab in the Lineberger Cancer Center is housed in 22-059. The Immunology part of the Core lab on the 4th floor of the Brinkhous-Bullitt Building is staying put.

Julie Nelson, Ph.D.

Core Director

Julie Nelson

Dr. Nelson is a Research Assistant Professor in Microbiology and Immunology and serves as the Director of the HIV/STD Laboratory Core. She has extensive expertise in HIV virology and molecular biology, working on HIV envelope evolution, genotyping of all regions of HIV, adapting viral load and sequencing assays to multiple specimen types (including breastmilk, genital secretions, cerebrospinal fluid, throatwash, dried blood spots, and urine), infection of different cell types with different strains of HIV, mutagenesis of HIV, and testing new antiretroviral compounds.

The University of North Carolina at Chapel Hill
CB# 7291
Chapel Hill, NC
jnelson@med.unc.edu
Fax: 919-966-9873
Office Phone: 919-966-6872

Kristina De Paris, Ph.D.

Associate Core Director

Kristina De Paris

Dr. De Paris is an Associate Professor in the Department of Microbiology and Immunology. Her research focuses on host-pathogen interactions in HIV-1 infection. The long-term goal of her work is to prevent HIV-1 transmission by breast-feeding. Towards this goal, her lab is performing pathogenesis and vaccine studies in the infant macaque model of oral SIV infection. Realizing that pediatric vaccine design and implementation require a detailed understanding of immune development in infants, her lab is trying to understand how molecular mechanisms of immune signaling differ between human infants and adults and how these responses mature during the first year of life. This knowledge will be instrumental for further vaccine optimization. Dr. De Paris is an experienced immunologist who is assisting clinicians in immunological aspects of their research, including flow cytometric sample analysis, measurement of biological mediators in various body fluids by ELISA or multiplex micro-bead analysis.

The University of North Carolina at Chapel Hill
Chapel Hill, NC
abelk@med.unc.edu
Office phone: 919-843-9560

Marcia Hobbs, Ph.D.

Associate Core Director

Dr. Hobbs is a Professor in the Departments of Medicine and Microbiology & Immunology. Marcia earned her BS from Duke University and her PhD from UNC; she has been on the faculty at Carolina since 1996. The Hobbs lab conducts translational research focused on non-viral sexually transmitted infections; the lab supports a variety of research projects aimed directly at diagnosis, treatment and prevention of sexually transmitted infections or the use of these infections as bio-markers in evaluating biomedical or behavioral interventions aimed at STI/HIV prevention.

The University of North Carolina at Chapel Hill
CB# 7031
Chapel Hill, NC
marcia_hobbs@med.unc.edu
Fax: 919-843-1015
Office Phone: 919-843-6893

John Schmitz, Ph.D.

Associate Core Director

Dr. Schmitz is a Professor of Pathology and Laboratory Medicine and Microbiology/Immunology and directs the Histocompatibility, Flow Cytometry and Clincal Immunology Laboratories at UNC Hospitals. Dr. Schmitz has experiences in the use of cytokine assays, flow cytometry including cell surface and intracellular cytokine assays as well as lymphocyte proliferation assays. He has used that experience in validating and implementing assays for HIV related research for over 15 years. Prior to establishing the Immunology Core Dr. Schmitz served for 8 years as the Director of the UNC Immunology Support Laboratory, one of 8 Immunology Cores within the ACTG. In addition to his experience providing support of basic, translational and clinical studies of HIV infection, Dr. Schmitz has extensive experience in diagnostic Immunology as director of the Clinical Immunology, Flow Cytometry and Histocompatibility Laboratories at UNC Hospitals. Dr. Schmitz’ 25 years of clinical research experience include assessment of antigen-specific humoral and cell-mediated immune responses, quantitation of soluble markers, immunogenetic testing and molecular diagnostics of infectious diseases.

The University of North Carolina at Chapel Hill
CB# 7600
Chapel Hill, NC
jschmitz@unch.unc.edu
Fax: 919-966-0486
Office Phone: 919-966-8453

Nicole Maponga

Laboratory Manager/Supervisor

Nicole Maponga

250 Bell Tower Drive
2156 Genome Sciences Building
Chapel Hill, NC
maponga@med.unc.edu
Fax: 919-966-9873
Office Phone: 919-966-6867

Takesha McMillion

Research Specialist

Takesha McMillion

250 Bell Tower Dr.
2124 Genome Sciences Building. CB 7291
Chapel Hill, NC
tbrksmc@med.unc.edu
Fax: 919-966-9873
Office Phone: 919-966-6867

Paul Alabanza

Research Specialist

Paul Alabanza

Charles West

Research Assistant

Charles West

250 Bell Tower Dr.
2158 Genome Sciences Building
Chapel Hill, NC
cbwest@med.unc.edu
Fax: 919-966-9873
Office Phone: 919-966-6867

Dana Lapple

Research Associate

Dana Lapple

Laura Finerty

Research Technician

William Wolf

Research Technician

Hannah Munro

Research Technician

 

UPDATED November 2019

RIGOR AND REPRODUCIBILITY FOR CFAR HIV/STD LABORATORY CORE

 

Eight steps to Rigorous and Reproducible Experiments in Biomolecular Research at UNC:

  1. If using a core facility, consult with the core staff in the planning stage. Consult with a statistician if you need help developing a Power Analysis to assure that your results will be adequately powered.
  2. Design your experiment with sufficient controls (rigor) and replicates (reproducibility).
  3. Assure that ALL of your reagents (antibodies, cell lines, mice) are fully validated (see below).
  4. Have a clear and detailed protocol (SOP) and data analysis plan. Assure that the protocol is strictly followed or that any deviation is well documented.
  5. Assure that the staff or students performing the experiment are well trained and understand each step and the importance of performing them precisely.
  6. Use only well-maintained instrumentation, preferably maintained and operated in a core facility with expert staff (see #1 above).
  7. Document all steps, reagents, equipment and data analysis methods used in the experiment. Assure that the both the documentation and the data itself are properly stored in a safe data management repository.
  8. Acknowledge the Cancer Center Support Grant (P30 CA016086) (if applicable), other grants that support the core, the core (by name), and core staff in publications.

 

Guide to Rigor and Reproducibility for the CFAR HIV/STD Laboratory Core

  1. Consult with the core staff in the planning stage. – Contact Julie Nelson, Core Director at jnelson@med.unc.edu or 919-966-6872
  2. Depending on the type of testing needed, appropriate controls and standards will be included. Replicates are important and can vary depending on the type of testing and power calculations. Flow cytometry, soluble marker quantitation, HIV quantitation, PSA detection, and HIV inhibition assays all have different controls and standards. Talk to us about the appropriate controls, standards, and replicates for your project.
  3. Validation of methods must be done when using a kit for a different sample type than the kit was designed for (soluble markers, etc.). The Core has validated methods for HIV quantitation from dried blood spots and PSA detection from vaginal swabs, for instance.
  4. The HIV/STD Laboratory Core provides training to ensure that all investigators are properly training in our technology unless we are contracted to do the work within the core. Training is provided includes BSL2+ work with HIV or human blood, MagPix and ELISA quantitation, ELISPOT reader use, flow on HIV-infected cells, and in vitro work with HIV. Contact us for more information.
  5. The CFAR HIV/STD Laboratory Core participates in external quality assurance for PBMC processing through the IQA and is CAP/CLIA accredited. The Core is also GCLP compliant in accordance with NIH DAIDS Network oversight.
  6. All equipment in the HIV/STD Laboratory Core is maintained per GCLP, CAP, or manufacturer’s instructions. In addition, QC measures are in place per GCLP and CAP.
  7. Detailed descriptions of experimental procedures and validations, including sample storage and processing, are documented electronically and in notebooks within the Core.
  8. Please acknowledge the UNC Center for AIDS Research HIV/STD Laboratory Core in your publications. Instructions for acknowledgment can be found here: http://unccfar.org/acknowledge-the-cfar/

 

UPDATED JULY 2019

ServicesTypeUNCNon-UNC
Assays (CAP/CLIA by arrangement)
A1 Qualitative RNA assay - Hologic Aptima on DTS**
A2 Quantitative HIV RNA - Abbott RealTime (blood/nonblood)**
A3 Quantitative HIV RNA - Hologic Aptima on Panther**
A4 Gonorrhea/Chlamydia NAAT - Hologic Aptima Combo2 on Panther**
A5 Trichomonas NAAT - Hologic Aptima TV on Panther**
A6 Mycoplasma genitalium NAAT - Hologic Aptima Mgen on Panther**
A7 Trichomonas culture assay (InPouch)**
A8 PSA testing - Abbott Architect**
A9 PSA rapid testing**
A10 DNA extraction for HLA1425
A11 HLA testing195304
A12 Flow Cytometry: staining and/or acquisition**
A13 ELISA**
A14 Multiplex cytokines (MagPix)**
A15 p24 (AlphaLISA)**
Services
S1 PBMC processing from each 30mL of blood**
S2 One spin processing and aliquotting**
S3 Two spin processing and aliquotting**
S4 Specimen aliquots (no processing)**
S5 Leukopak processing and storage of viable cells**
S6 Phlebotomy4066
S7 Donor recruitment for phlebotomy1015.55
S8 Specimen handling charge (per box)1163
S9 Dry ice shipping (plus shipper fees)113263
S10 Liquid nitrogen shipping (dry shipper) (plus shipper fees)144570
S11 Analysis/Labor (per hour)3655.98
S12 Consultation (per hour)60117
S13 ELISPOT use (non CFAR users, per hour)5077.75
S14 MagPix use (per run)5077.75
S15 Specimen storage at -20 or -80 (per box per year)34.665
S16 Specimen storage in liquid nitrogen (per box per year)57.775
*Cost will be determined for each project to include kits, supplies, and labor All projects
with non-UNC funds will have an additional 555% fee

PUBLICATIONS

2019

Bekhbat M, Mehta CC, Kelly SD, Vester A, Ofotokun I, Felger J, Wingood G, Anastos K, Gustafson DR, Kassaye S, Milam J, Aouizerat B, Weber K, Golub ET, Moore MF, Diclemente R, Fischl M, Kempf M-C, Maki P, Neigh GN. HIV and symptoms of depression are independently associated with impaired glucocorticoid signaling. Psychoneuroendocrinology. 2018 Oct;96:118–125. PMID: 29936334. PMCID: PMC6131054

Bertero L, Joseph SB, Trunfio M, Allice T, Catera S, Imperiale D, Cassoni P, Kincer LP, Pirriatore V, Ghisetti V, Amasio E, Zanusso G, Bonora S, Di Perri G, Calcagno A. HIV-1 detection in the olfactory mucosa of HIV-1-infected participants. AIDS 2019 Mar 15;33(4):665–674. PMID:30608272 

Chinula L, Nelson JAE, Wiener J, Tang JH, Hurst S, Tegha G, Msika A, Ellington S, Hosseinipour MC, Mataya R, Haddad LB, Kourtis AP. Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial. Contraception. 2018 Sep;98(3):193–198. PMID: 29746813. PMCID: PMC6143482

Clutton G, Mollan K, Hudgens M, Goonetilleke N. A Reproducible, Objective Method Using MitoTracker® Fluorescent Dyes to Assess Mitochondrial Mass in T Cells by Flow Cytometry. Cytom Part J Int Soc Anal Cytol. 2018 Dec 21; PMID: 30576071. PMCID:PMC6461488

Colasanti J, Galaviz KI, Christina Mehta C, Palar K, Schneider MF, Tien P, Adimora AA, Alcaide M, Cohen MH, Gustafson D, Karim R, Merenstein D, Sharma A, Wingood G, Marconi VC, Ofotokun I, Ali MK. Room for Improvement: The HIV-Diabetes Care Continuum Over 15 Years in the Women’s Interagency HIV Study. Open Forum Infect Dis. 2018 Jun 1;5(6):ofy121. PMID: 29942823. PMCID: PMC6007350

Cranston RD, Cespedes MS, Paczuski P, Yang M, Coombs RW, Dragavon J, Saah A, Godfrey C, Webster-Cyriaque JY, Chiao EY, Bastow B, Wilkin T, ACTG 5298 Study Team. High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298. Sex Transm Dis. 2018;45(4):266–271. PMID: 29528986. PMCID: PMC5868482

Dennis AM, Cohen MS, Rucinski KB, Rutstein SE, Powers KA, Pasquale DK, Phiri S, Hosseinipour MC, Kamanga G, Nsona D, Massa C, Hoffman IF, Pettifor AE, Miller WC. HIV-1 transmission among persons with acute HIV-1 infection in Malawi: demographic, behavioral and phylogenetic relationships. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018 Nov 26; PMID: 30476007

Dumond JB, Greene SA, Prince HM, Chen J, Maas BM, Sykes C, Schauer AP, Blake KH, Nelson JAE, Gay CL, Kashuba ADM, Cohen MS. Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract. Antivir Ther. 2019;24(1):45–50. PMID: 30375984

Ewing AC, Ellington SR, Wiener JB, Chasela CS, Tegha G, Nelson JAE, Jamieson DJ, van der Horst C, Kourtis AP, BAN Study Team. Predictors of Perinatal HIV Transmission Among Women Without Prior Antiretroviral Therapy in a Resource-Limited Setting: The BAN Study. Pediatr Infect Dis J. 2018 Oct 30; PMID:30985546 . PMCID: PMC6302572

Gallichotte EN, Baric TJ, Nivarthi U, Delacruz MJ, Graham R, Widman DG, Yount BL, Durbin AP, Whitehead SS, de Silva AM, Baric RS. Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization. Cell Rep. 2018 Oct 30;25(5):1214–1224. PMID: 30380413. PMCID: PMC6226424

Gandhi M, Bacchetti P, Ofokotun I, Jin C, Ribaudo HJ, Haas DW, Sheth AN, Horng H, Phung N, Kuncze K, Okochi H, Landovitz RJ, Lennox J, Currier JS, AIDS Clinical Trials Group (ACTG) 5257 Study Team. Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naive Clinical Trial. Clin Infect Dis Off Publ Infect Dis Soc Am. 2019 Mar 5;68(6):1044–1047. PMID: 30184104. PMCID: PMC6399433

Garrido C, Tolstrup M, Søgaard OS, Rasmussen TA, Allard B, Soriano-Sarabia N, Archin NM, Margolis DM. In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals. AIDS 2019 Mar 15;33(4):605–613. PMID: 30830886. PMCID: PMC6400302

Gradissimo A, Lam J, Attonito JD, Palefsky J, Massad LS, Xie X, Eltoum I-E, Rahangdale L, Fischl MA, Anastos K, Minkoff H, Xue X, D’Souza G, Flowers LC, Colie C, Shrestha S, Hessol NA, Strickler HD, Burk RD. Methylation of High-Risk Human Papillomavirus Genomes Are Associated with Cervical Precancer in HIV-Positive Women. Cancer Epidemiol Prev Biomark. 2018 Dec 1;27(12):1407–1415. PMID: 30237251. PMCID: PMC6279505

Hightow-Weidman LB, Magnus M, Beauchamp G, Hurt CB, Shoptaw S, Emel L, Piwowar-Manning E, Mayer KH, Nelson LE, Wilton L, Watkins P, Whitfield D, Fields SD, Wheeler D. Incidence and Correlates of STIs among Black Men who have Sex with Men Participating in the HPTN 073 PrEP Study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2019 Jan 7; PMID: 30615169

Kelly SG, Wu K, Tassiopoulos K, Erlandson KM, Koletar SL, Palella FJ, ACTG A5322 Study Team. Frailty is an independent risk factor for mortality, cardiovascular disease, bone disease and diabetes among aging adults with HIV. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018 Dec 24; PMID: 30590451

Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, Zhang Y, Tolley E, Sugarman J, Kofron R, Adeyeye A, Burns D, Rinehart AR, Margolis D, Spreen WR, Cohen MS, McCauley M, Eron JJ. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018 Nov;15(11):e1002690. PMID: 30408115. PMCID: PMC6224042

Nag M, De Paris K, Fogle JE. Epigenetic modulation of CD8+ T cell function in lentivirus infections: a review. Viruses. 2018a;10(5):227. PMID: 29710792. PMCID: PMC5977220

Nag M, Wang Y, De Paris K, Fogle JE. Histone modulation blocks Treg-induced Foxp3 binding to the IL-2 promoter of virus-specific CD8+ T cells from feline immunodeficiency virus infected cats. Viruses. 2018b;10(6):E287. PMID: 29861472. PMCID: PMC6024775

Omana-Zapata I, Mutschmann C, Schmitz J, Gibson S, Judge K, Aruda Indig M, Lu B, Taufman D, Sanfilippo AM, Shallenberger W, Graminske S, McLean R, Hsen RI, d’Empaire N, Dean K, O’Gorman M. Accurate and reproducible enumeration of T-, B-, and NK lymphocytes using the BD FACSLyric 10-color system: A multisite clinical evaluation. PloS One. 2019;14(1):e0211207. PMID: 30689658. PMCID: PMC6349332

Prather AA, Epel ES, Portela Parra E, Coccia M, Puterman E, Aiello AE, Dhabhar FS. Associations between chronic caregiving stress and T cell markers implicated in immunosenescence. Brain Behav Immun. 2018 Oct;73:546–549. PMID: 29935942. PMCID: PMC6129414

Rutstein SE, Chen JS, Nelson JAE, Phiri S, Miller WC, Hosseinipour MC. High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up. AIDS Res Ther. 2019 Feb 22;16(1):5. PMID: 30795780. PMCID: PMC6385432

Scheidell JD, Beau De Rochars VM, Séraphin MN, Hobbs MM, Morris JG, Célestin JP, Cottler LB, Khan MR. Socioeconomic Vulnerability and Sexually Transmitted Infection Among Pregnant Haitian Women. Sex Transm Dis. 2018 Sep;45(9):626–631. PMID: 29697553. PMCID: PMC6086731

Shivakoti R, Ewald ER, Gupte N, Yang W-T, Kanyama C, Cardoso SW, Santos B, Supparatpinyo K, Badal-Faesen S, Lama JR, Lalloo U, Zulu F, Pawar JS, Riviere C, Kumarasamy N, Hakim J, Pollard R, Detrick B, Balagopal A, Asmuth DM, Semba RD, Campbell TB, Golub J, Gupta A, NWCS 319 and ACTG PEARLS Study Team. Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial. Clin Nutr Edinb Scotl. 2018 May 29; PMID: 29885777. PMCID: PMC6265110

Sung JA, Patel S, Clohosey ML, Roesch L, Tripic T, Kuruc JD, Archin N, Hanley PJ, Cruz CR, Goonetilleke N, Eron JJ, Rooney CM, Gay CL, Bollard CM, Margolis DM. HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals. Mol Ther J Am Soc Gene Ther. 2018 Oct 3;26(10):2496–2506. PMID: 30249388. PMCID: PMC6171327

Trunfio M, Joseph SB, Ghisetti V, Romito A, Martini C, Cusato J, Audagnotto S, Pesci Kincer L, Ferrara M, Sala A, Imperiale D, Di Perri G, Calcagno A. Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia. J Neurovirol. 2018 Feb;24(1):132–136. PMID: 29243133

Van Wagoner N, Fife K, Leone PA, Bernstein DI, Warren T, Panther L, Novak RM, Beigi R, Kriesel J, Tyring S, Koltun W, Lucksinger G, Morris A, Zhang B, McNeil LK, Tasker S, Hetherington S, Wald A. Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial. J Infect Dis. 2018 Nov 5;218(12):1890–1899. PMID:29982727 

Wang Y, Nag M, Tuohy JL, De Paris K, Fogle JE. T Regulatory Cell Induced Foxp3 Binds the IL2, IFNγ, and TNFα Promoters in Virus-Specific CD8+ T Cells from Feline Immunodeficiency Virus Infected Cats. AIDS Res Hum Retroviruses. 2018;34(3):269–276. PMID: 29037051. PMCID: PMC5863085

Weber MD, Andrews E, Prince HA, Sykes C, Rosen EP, Bay C, Shaheen NJ, Madanick RD, Dellon ES, De Paris K, Nelson JAE, Gay CL, Kashuba ADM. Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gut-Associated Lymphoid Tissue of HIV-Infected Men and Women. Antivir Ther. 2018;23(6):495-504. PMID: 29714167

Wechsberg WM, Bonner CP, Zule WA, van der Horst C, Ndirangu J, Browne FA, Kline TL, Howard BN, Rodman NF. Addressing the nexus of risk: Biobehavioral outcomes from a cluster randomized trial of the Women’s Health CoOp Plus in Pretoria, South Africa. Drug Alcohol Depend. 2019 Feb 1;195:16–26. PMID: 30562676. PMCID: PMC6415667

Wheeler DP, Fields SD, Beauchamp G, Chen YQ, Emel LM, Hightow-Weidman L, Hucks-Ortiz C, Kuo I, Lucas J, Magnus M, Mayer KH, Nelson LE, Hendrix CW, Piwowar-Manning E, Shoptaw S, Watkins P, Watson CC, Wilton L. Pre-exposure prophylaxis initiation and adherence among Black men who have sex with men (MSM) in three US cities: results from the HPTN 073 study. J Int AIDS Soc. 2019 Feb;22(2):e25223. PMID: 30768776. PMCID: PMC6376611

Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG, VHICS Study Team. Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). Open Forum Infect Dis. 2018 Jun;5(6):ofy103. PMID: 29977962. PMCID: PMC6016417

2018

Archin NM, Kirchherr JL, Sung JA, Clutton G, Sholtis K, Xu Y, Allard B, Stuelke E, Kashuba AD,
Kuruc JD, Eron J, Gay CL, Goonetilleke N, Margolis DM. Interval dosing with the HDAC
inhibitor vorinostat effectively reverses HIV latency. J Clin Invest. 2017 Aug 1;127(8):3126–3135.
PMID: 28714868. PMCID: PMC5531421

Bellavia A, Williams PL, DiMeglio LA, Hazra R, Abzug MJ, Patel K, Jacobson DL, Van Dyke RB,
Geffner ME, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)
P219/219C Study, and the Pediatric HIV/AIDS Cohort Study (PHACS). Delay in sexual
maturation in perinatally HIV-infected youths is mediated by poor growth. AIDS Lond Engl. 2017
Jun 1;31(9):1333–1341. PMID: 28358737. PMCID: PMC5472204

Celum C, Hong T, Cent A, Donnell D, Morrow R, Baeten JM, Firnhaber C, Grinsztejn B,
Hosseinipour MC, Lalloo U, Nyirenda M, Riviere C, Sanchez J, Santos B, Supparatpinyo K,
Hakim J, Kumarasamy N, Campbell TB, ACTG PEARLS/A5175 Team. Herpes Simplex Virus
Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as
Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. J
Infect Dis. 2017 15;215(6):907–910. PMID: 28453835. PMCID: PMC5406847

Chen J, Akhtari FS, Wagner MJ, Suzuki O, Wiltshire T, Motsinger-Reif AA, Dumond JB.
Pharmacogenetic Analysis of the Model-Based Pharmacokinetics of Five Anti-HIV Drugs: How
Does This Influence the Effect of Aging? Clin Transl Sci. 2018 Mar;11(2):226–236. PMID:
29205871. PMC5866997.

Cheng L, Yu H, Li G, Li F, Ma J, Li J, Chi L, Zhang L, Su L. Type I interferons suppress viral
replication but contribute to T cell depletion and dysfunction during chronic HIV-1 infection. JCI
Insight. 2017 Jun 15;2(12). PMID: 28614789. PMCID: PMC5470878

Cho H, Mbai I, Luseno WK, Hobbs M, Halpern C, Hallfors DD. School Support as Structural HIV
Prevention for Adolescent Orphans in Western Kenya. J Adolesc Health Off Publ Soc Adolesc
Med. 2018 Jan;62(1):44–51. PMID: 29107569. PMCID: PMC5742035

Dela Peña-Ponce MG, Rodriguez-Nieves J, Bernhardt J, Tuck R, Choudhary N, Mengual M,
Mollan KR, Hudgens MG, Peter-Wohl S, De Paris K. Increasing JAK/STAT Signaling Function
of Infant CD4(+) T Cells during the First Year of Life. Front Pediatr. 2017;5:15. PMID: 28271056.
PMCID: PMC5318443

Eke AC, Chakhtoura N, Kashuba A, Best BM, Sykes C, Wang J, Stek AM, Smith E, Calabrese S,
Capparelli EV, Mirochnick M, IMPAACT P1026s Protocol Team. Rilpivirine Plasma and Cervico-
Vaginal Concentrations in Women During Pregnancy and Postpartum. J Acquir Immune Defic
Syndr. 2018 Mar 8; PMID: 29528944

Flynn PM, Taha TE, Cababasay M, Fowler MG, Mofenson LM, Owor M, Fiscus S, Stranix-
Chibanda L, Coutsoudis A, Gnanashanmugam D, Chakhtoura N, McCarthy K, Mukuzunga C,
Makanani B, Moodley D, Nematadzira T, Kusakara B, Patil S, Vhembo T, Bobat R, Mmbaga BT,
Masenya M, Nyati M, Theron G, Mulenga H, Butler K, Shapiro DE, PROMISE Study Team.
Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal
Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-
1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-
Label, Clinical Trial. J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):383–392. PMID: 29239901.
PMC5825265.

Gallo MF, Legardy-Williams J, Steiner MJ, Macaluso M, Carter M, Hobbs MM, Hylton-Kong T,
Anderson C, Costenbader E, Warner L. Sexual Relationship Power and Semen Exposure
Among Female Patients at a Sexually Transmitted Infection Clinic in Kingston, Jamaica. Arch
Sex Behav. 2017 Oct;46(7):2157–2164. PMID: 27305908. PMCID: PMC5500443

Gandhi M, Gandhi RT, Stefanescu A, Bosch RJ, Cyktor JC, Horng H, Louie A, Phung N, Eron
JJ, Hogg E, Macatangay BJC, Hensel C, Fletcher CV, Mellors JW, McMahon DK, A5321 Team.
Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV
Persistence or Inflammation Among Individuals on Suppressive ART. J Infect Dis. 2018 Feb 26;
PMID: 29529230

Gay CL, DeBenedette MA, Tcherepanova IY, Gamble A, Lewis WE, Cope AB, Kuruc JD,
McGee KS, Kearney MF, Coffin JM, Archin NM, Hicks CB, Eron JJ, Nicolette CA, Margolis
DM. Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. AIDS Res Hum Retroviruses. 2018 Jan;34(1):111–122. PMID: 28636433.
PMC5771540

Gay CL, Bosch RJ, Ritz J, Hataye JM, Aga E, Tressler RL, Mason SW, Hwang CK, Grasela DM,
Ray N, Cyktor JC, Coffin JM, Acosta EP, Koup RA, Mellors JW, Eron JJ, AIDS Clinical Trials
5326 Study Team. Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected
Participants on Suppressive Antiretroviral Therapy. J Infect Dis. 2017 Jun 1;215(11):1725–1733.
PMID: 28431010. PMCID: PMC5790148

Ghulam-Smith M, Olson A, White LF, Chasela CS, Ellington SR, Kourtis AP, Jamieson DJ,
Tegha G, van der Horst CM, Sagar M. Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody
Response Associates with Enhanced Transmission and Infant Morbidity. mBio. 2017 Oct
24;8(5). PMID: 29066544. PMCID: PMC5654929

Hampel D, Shahab-Ferdows S, Gertz E, Flax VL, Adair LS, Bentley ME, Jamieson DJ, Tegha
G, Chasela CS, Kamwendo D, van der Horst CM, Allen LH. The effects of a lipid-based nutrient
supplement and antiretroviral therapy in a randomized controlled trial on iron, copper, and zinc in
milk from HIV-infected Malawian mothers and associations with maternal and infant biomarkers.
Matern Child Nutr. 2018 Apr;14(2):e12503. PMID: 28851037. PMCID: PMC5832511

Hosseinipour M, Nelson JAE, Trapence C, Rutstein SE, Kasende F, Kayoyo V, Kaunda-
Khangamwa B, Compliment K, Stanley C, Cataldo F, van Lettow M, Rosenberg NE, Tweya H,
Gugsa S, Sampathkumar V, Schouten E, Eliya M, Chimbwandira F, Chiwaula L, Kapito-Tembo
A, Phiri S, PURE Malawi Consortium. Viral Suppression and HIV Drug Resistance at 6 Months
Among Women in Malawi’s Option B+ Program: Results From the PURE Malawi Study. J Acquir
Immune Defic Syndr 1999. 2017 Jun 1;75 Suppl 2:S149–S155. PMID: 28498184. PMCID:
PMC5431274

Jao J, Yu W, Patel K, Miller TL, Karalius B, Geffner ME, DiMeglio LA, Mirza A, Chen JS, Silio M,
McFarland EJ, Van Dyke RB, Jacobson D, Pediatric HIV/AIDS Cohort Study (PHACS)
Adolescent Master Protocol (AMP) study. Improvement in lipids after switch to boosted
atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease
inhibitors: results from the Pediatric HIV/AIDS Cohort Study. HIV Med. 2018 Mar;19(3):175–183.
PMID: 29159965. PMCID: PMC5821593

Jao J, Kacanek D, Williams PL, Geffner ME, Livingston EG, Sperling RS, Patel K, Bardeguez
AD, Burchett SK, Chakhtoura N, Scott GB, Van Dyke RB, Abrams EJ. Birth Weight and Preterm
Delivery Outcomes of Perinatally vs Nonperinatally Human Immunodeficiency Virus-Infected
Pregnant Women in the United States: Results From the PHACS SMARTT Study and IMPAACT
P1025 Protocol. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017 Sep 15;65(6):982–989. PMID:
28575201. PMCID: PMC5849107

Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, Buschur SL, Acosta EP, Smith E,
Chakhtoura N, Burchett S, Mirochnick M, IMPAACT P1026s Protocol Team. Dolutegravir
pharmacokinetics in pregnant and postpartum women living with HIV. AIDS Lond Engl. 2018 Mar
27;32(6):729–737. PMID: 29369162. PMCID: PMC5854536

Patel S, Lam S, Sung J, Cruz R, Goonetilleke N, Xu Y, Kuruc J, Gay C, Jones B, Shpall E,
Margolis D, Ambinder R, Bollard C. HIV specific T cells generated from HIV naive adult
and cord blood donors target a range of novel viral epitopes – implications for a cure
strategy after allogeneic HSCT and CBT. Cytotherapy. 2017;19:S41-2. (poster abstract)

Pinto JA, Capparelli EV, Warshaw M, Zimmer B, Cressey TR, Spector SA, Qin M, Smith B,
Siberry GK, Mirochnick M, IMPAACT P1083 Team. A Phase II/III Trial of Lopinavir/Ritonavir
Dosed According to the WHO Pediatric Weight Band Dosing Guidelines. Pediatr Infect Dis J.
2018 Feb;37(2):e29–e35. PMID: 29088027. PMCID: PMC5762400

Scheidell J, Beau De Rochars V, Séraphin M, Hobbs M, Morris J, Célestin J, Cottier L, Khan M.
Socioeconomic Vulnerability and Sexually Transmitted Infection among Pregnant Haitian
Women. Sex Transm Dis. 2018;Sep;45(9):626-631. PMID: 29697553 PMCID: PMC6086731.

Seña AC, Lee JY, Schwebke J, Philip SS, Wiesenfeld HC, Rompalo AM, Cook RL, Hobbs MM.
A silent epidemic: the prevalence, incidence and persistence of Mycoplasma genitalium among
young, asymptomatic high-risk women in the United States. Clin Infect Dis Off Publ Infect Dis
Soc Am. 2018 Jan 12; PMID: 29342269

Smith JS, Des Marais AC, Deal AM, Richman AR, Perez-Heydrich C, Yen-Lieberman B, Barclay
L, Belinson J, Rinas A, Brewer NT. Mailed Human Papillomavirus Self-Collection With
Papanicolaou Test Referral for Infrequently Screened Women in the United States. Sex Transm
Dis. 2018 Jan;45(1):42–48. PMID: 28876298. PMCID: PMC5846187

Sung JA, Sholtis K, Kirchherr J, Kuruc JD, Gay CL, Nordstrom JL, Bollard CM, Archin NM,
Margolis DM. Vorinostat Renders the Replication-Competent Latent Reservoir of Human
Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells. EBioMedicine. 2017
Sep;23:52–58. PMID: 28803740. PMCID: PMC5605299

Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, Godfrey C, Sax PE, Acosta E,
Haas D, Smith KY, Sha B, Van Dam C, Gulick RM. ACTG A5353: A pilot study of dolutegravir
plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000
copies/mL. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017 Dec 14; PMID: 29253097. PMCID: PMC5961075.

Utay NS, Kitch DW, Yeh E, Fichtenbaum CJ, Lederman MM, Estes JD, Deleage C, Magyar C,
Nelson SD, Klingman KL, Bastow B, Luque AE, McComsey GA, Douek DC, Currier JS, Lake JE,
A5317 team. Telmisartan Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than
Continued ART Alone. J Infect Dis. 2018 Feb 1; PMID: 29401318.  PMC5946950.

Warshaw MG, Siberry GK, Williams P, Decker MD, Jean-Philippe P, Lujan-Zilbermann J.
Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in
Previously Immunized HIV-Infected Children and Youth. J Pediatr Infect Dis Soc. 2017 Sep
1;6(3):e69–e74. PMID: 28339668. PMCID: PMC5907864.

Weber MD, Andrews E, Prince HA, Sykes C, Rosen EP, Bay C, Shaheen NJ, Madanick RD,
Dellon ES, De Paris K, Nelson JAE, Gay CL, Kashuba ADM. Virologic and Immunologic
Responses to Raltegravir and Dolutegravir in the Gut-Associated Lymphoid Tissue of HIVInfected
Men and Women. Antivir Ther. 2018;in press. 

2017

Archin NM, Kirchherr JL, Sung JA, Clutton G, Sholtis K, Xu Y, Allard B, Stuelke E, Kashuba AD,
Kuruc JD, Eron J, Gay CL, Goonetilleke N, Margolis DM. Interval dosing with the HDAC
inhibitor vorinostat effectively reverses HIV latency. J Clin Invest. 2017 Aug 1;127(8):3126–3135.
PMID: 28714868. PMCID: PMC5531421

Bellavia A, Williams PL, DiMeglio LA, Hazra R, Abzug MJ, Patel K, Jacobson DL, Van Dyke RB,
Geffner ME, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)
P219/219C Study, and the Pediatric HIV/AIDS Cohort Study (PHACS). Delay in sexual
maturation in perinatally HIV-infected youths is mediated by poor growth. AIDS Lond Engl. 2017
Jun 1;31(9):1333–1341. PMID: 28358737. PMCID: PMC5472204

Celum C, Hong T, Cent A, Donnell D, Morrow R, Baeten JM, Firnhaber C, Grinsztejn B,
Hosseinipour MC, Lalloo U, Nyirenda M, Riviere C, Sanchez J, Santos B, Supparatpinyo K,
Hakim J, Kumarasamy N, Campbell TB, ACTG PEARLS/A5175 Team. Herpes Simplex Virus
Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. J
Infect Dis. 2017 15;215(6):907–910. PMID: 28453835. PMCID: PMC5406847

Cheng L, Yu H, Li G, Li F, Ma J, Li J, Chi L, Zhang L, Su L. Type I interferons suppress viral
replication but contribute to T cell depletion and dysfunction during chronic HIV-1 infection. JCI
Insight. 2017 Jun 15;2(12). PMID: 28614789. PMCID: PMC5470878

Dela Peña-Ponce MG, Rodriguez-Nieves J, Bernhardt J, Tuck R, Choudhary N, Mengual M,
Mollan KR, Hudgens MG, Peter-Wohl S, De Paris K. Increasing JAK/STAT Signaling Function
of Infant CD4(+) T Cells during the First Year of Life. Front Pediatr. 2017;5:15. PMID: 28271056.
PMCID: PMC5318443

Gallo MF, Legardy-Williams J, Steiner MJ, Macaluso M, Carter M, Hobbs MM, Hylton-Kong T,
Anderson C, Costenbader E, Warner L. Sexual Relationship Power and Semen Exposure
Among Female Patients at a Sexually Transmitted Infection Clinic in Kingston, Jamaica. Arch
Sex Behav. 2017 Oct;46(7):2157–2164. PMID: 27305908. PMCID: PMC5500443

Gay CL, Bosch RJ, Ritz J, Hataye JM, Aga E, Tressler RL, Mason SW, Hwang CK, Grasela DM,
Ray N, Cyktor JC, Coffin JM, Acosta EP, Koup RA, Mellors JW, Eron JJ, AIDS Clinical Trials
5326 Study Team. Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected
Participants on Suppressive Antiretroviral Therapy. J Infect Dis. 2017 Jun 1;215(11):1725–1733.
PMID: 28431010. PMCID: PMC5790148

Ghulam-Smith M, Olson A, White LF, Chasela CS, Ellington SR, Kourtis AP, Jamieson DJ,
Tegha G, van der Horst CM, Sagar M. Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody
Response Associates with Enhanced Transmission and Infant Morbidity. mBio. 2017 Oct
24;8(5). PMID: 29066544. PMCID: PMC5654929

Hosseinipour M, Nelson JAE, Trapence C, Rutstein SE, Kasende F, Kayoyo V, Kaunda-
Khangamwa B, Compliment K, Stanley C, Cataldo F, van Lettow M, Rosenberg NE, Tweya H,
Gugsa S, Sampathkumar V, Schouten E, Eliya M, Chimbwandira F, Chiwaula L, Kapito-Tembo
A, Phiri S, PURE Malawi Consortium. Viral Suppression and HIV Drug Resistance at 6 Months
Among Women in Malawi’s Option B+ Program: Results From the PURE Malawi Study. J Acquir
Immune Defic Syndr 1999. 2017 Jun 1;75 Suppl 2:S149–S155. PMID: 28498184. PMCID:
PMC5431274

Jao J, Kacanek D, Williams PL, Geffner ME, Livingston EG, Sperling RS, Patel K, Bardeguez
AD, Burchett SK, Chakhtoura N, Scott GB, Van Dyke RB, Abrams EJ. Birth Weight and Preterm
Delivery Outcomes of Perinatally vs Nonperinatally Human Immunodeficiency Virus-Infected
Pregnant Women in the United States: Results From the PHACS SMARTT Study and IMPAACT
P1025 Protocol. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017 Sep 15;65(6):982–989. PMID:
28575201.PMCID: PMC5849107

Sung JA, Sholtis K, Kirchherr J, Kuruc JD, Gay CL, Nordstrom JL, Bollard CM, Archin NM,
Margolis DM. Vorinostat Renders the Replication-Competent Latent Reservoir of Human
Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells. EBioMedicine. 2017
Sep;23:52–58. PMID: 28803740. PMCID: PMC5605299

Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, Godfrey C, Sax PE, Acosta E,
Haas D, Smith KY, Sha B, Van Dam C, Gulick RM. ACTG A5353: A pilot study of dolutegravir
plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000
copies/mL. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017 Dec 14; PMID: 29253097

Warshaw MG, Siberry GK, Williams P, Decker MD, Jean-Philippe P, Lujan-Zilbermann J.
Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in
Previously Immunized HIV-Infected Children and Youth. J Pediatr Infect Dis Soc. 2017 Sep
1;6(3):e69–e74. PMID: 28339668 

2016
2015

Allen LH, Hampel D, Shahab-Ferdows S, York ER, Adair LS, Flax VL, Tegha G, Chasela CS, Kamwendo D, Jamieson DJ, Bentley ME. Antiretroviral therapy provided to HIV-infected Malawian women in a randomized trial diminishes the positive effects of lipid-based nutrient supplements on breast-milk B vitamins. Am J Clin Nutr. 2015 Dec;102(6):1468-74.PubMed PMID: 26537941; PubMed Central PMCID: PMC4658457.

Collins-Fairclough AM, Dennis AM, Nelson JA, Weir SS, Figueroa JP. HIV Drug Resistance Surveillance Among Jamaican Men Who Have Sex with Men Should Be Prioritized for Reducing HIV Transmission. AIDS Res Hum Retroviruses. 2015 Aug;31(8):841-4. PubMed PMID: 26133540; PubMed Central PMCID: PMC4533094.

Cope AB, Powers KA, Kuruc JD, Leone PA, Anderson JA, Ping LH, Kincer LP, Swanstrom R, Mobley VL, Foust E, Gay CL, Eron JJ, Cohen MS, Miller WC. Ongoing HIV Transmission and the HIV Care Continuum in North Carolina. PLoS One. 2015 Jun 4;10(6):e0127950. PubMed PMID: 26042804; PubMed Central PMCID: PMC4456412.

Flax VL, Adair LS, Allen LH, Shahab-Ferdows S, Hampel D, Chasela CS, Tegha G, Daza EJ, Corbett A, Davis NL, Kamwendo D, Kourtis AP, van der Horst CM, Jamieson DJ, Bentley ME; BAN Study Team. Plasma Micronutrient Concentrations Are Altered by Antiretroviral Therapy and Lipid-Based Nutrient Supplements in Lactating HIV-Infected Malawian Women. J Nutr. 2015 Aug;145(8):1950-7. PMC4516772

King CC, Kourtis AP, Persaud D, Nelson JAE, Ziemniak C, Hudgens MG, Tegha G, Chasela CS, Jamieson DJ, van der Horst CM. Delayed HIV Detection among Infants Exposed to Postnatal ARV Prophylaxis during Breastfeeding. AIDS 2015 Sep 24;29(15):1953-61. PMC4665628

Nelson JAE, Fokar A, Hudgens MG, Compliment KJ, Hawkins JT, Tegha G, Kamwendo DD, Kayira D, Mofolo IA, Kourtis AP, Jamieson DJ, van der Horst CM, Fiscus SA. Frequent Nevirapine Resistance in Infants Infected by HIV-1 Via Breastfeeding while on Nevirapine Prophylaxis: Results of the BAN Study. AIDS. 2015 Oct 23;29(16):2131-8. PMC4715989

Pollara J, McGuire E, Fouda GG, Rountree W, Eudailey J, Overman RG, Seaton KE, Deal A, Edwards RW, Tegha G, Kamwendo D, Kumwenda J, Nelson JA, Liao HX, Brinkley C, Denny TN, Ochsenbauer C, Ellington S, King CC, Jamieson DJ, van der Horst C, Kourtis AP, Tomaras GD, Ferrari G, Permar SR. Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. J Virol. 2015 Oct;89(19):9952-61. PubMed PMID: 26202232; PubMed Central PMCID: PMC4577885.

Widen EM, Bentley ME, Chasela CS, Kayira D, Flax VL, Kourtis AP, Ellington SR, Kacheche Z, Tegha G, Jamieson DJ, van der Horst CM, Allen LH, Shahab-Ferdows S, Adair LS; BAN Study Team. Antiretroviral Treatment Is Associated With Iron Deficiency in HIV-Infected Malawian Women That Is Mitigated With Supplementation, but Is Not Associated With Infant Iron Deficiency During 24 Weeks of Exclusive Breastfeeding. J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):319-28. Erratum in: J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):e184. PubMed PMID: 25723140; PubMed Central PMCID: PMC4506710.